anti-anb3 integrin
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2002 (NCT00052403)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Integrin subunit alpha 2b/beta-3INHIBITOR
Integrin subunit alpha 2b/beta-3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-anb3 integrin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00052403 | Phase 1 | Feb 1, 2002 | Harper Hospital, National Cancer Institute (NCI), Wayne State University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harper Hospital | Academic/Hospital | 1 | 0 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2002 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2002 |
3 organizations
Page 1 / 1